Physical therapy treatment for migraine
Conditions
Interventions
1. Therapeutic Education Group: There will be 25 participants in this group, which will be the active control. They will attend a single appointment of approximately 60 minutes, aimed at addressing pa
E02.190.599
E02.760.169.063.500.387.750
E02.779.474
Sponsors
Faculdade de Medicina de Ribeirão Preto
Faculdade de Medicina de Ribeirão Preto
Eligibility
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: individuals of both sexes, aged between 18 and 55 years, diagnosed with migraine according to the 3rd edition of the International Classification of Headache Disorders, with at least 3 days of migraine per month, in the last month.
Exclusion criteria
Exclusion criteria: other concomitant primary / secondary headaches, including tension-type and cervicogenic headache; history of facial or neck trauma; history of cervical disc herniation or cervical osteoarthritis; any systemic degenerative disease (for example: rheumatoid arthritis and lupus erythematosus); pregnancy; physiotherapy treatment for craniocervical dysfunction in the previous year; and / or who has started a new pharmacological treatment for the disease in the last three months prior to the screening of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Decrease of at least 6 points in the headache-related impact of, measured by the Headache Impact Test - HIT-6. which will be applied at the baseline, at four, eight, and twelve weeks of the treatment, and at the follow-ups at 1-mo, 2-mo, and 4-mo. | — |
Secondary
| Measure | Time frame |
|---|---|
| Expected outcome 3: Increased pressure pain threshold, measured by a digital manual dynamometer (DDK-20 Kratos®) at the baseline and at four, eight, and twelve weeks of treatment.;Expected outcome 4: Increased cervical range of motion for flexion (>7.4°), extension (>4.9°), lateral flexion (>4.8°) and rotation (>7.9°), assessed using the Multi-Cervical Unit equipment (MCU, BTE technologies, Inc, 2006) at the baseline and at four, eight, and twelve weeks of treatment.;Expected outcome 5: Increased cervical muscle strength for flexion(>7.6), extension (>13.3) and lateral flexion (>9.8), assessed using the Multi-Cervical Unit equipment (MCU, BTE technologies, Inc, 2006) at the baseline and at four, eight, and twelve weeks of treatment.;Expected outcome 6: Upper cervical mobility 34°, measured the Flexion Rotation Test, using the Cervical Range of Motion device. This assessment will be performed at the baseline and at four, eight, and twelve weeks of treatment.;Expected outcome 7: Increased cervical muscle performance, assessed through the Craniocervical Flexion Test, using a pressure biofeedback unit (Stabilizer Chattanooga South Pacific; USA). This test will be performed at the baseline and at four, eight, and twelve weeks of treatment.;Decrease greater than 5 points of neck pain disability, assessed through the Neck Disability Index, at the baseline, at four, eight and twelve weeks of the treatment, and at the follow-ups at 1-mo, 2-mo and 4-months.;Expected outcome 9: Decreased cutaneous allodynia assessed using the 12-item Allodynia Symptom Checklist questionnaire, that will be applied at the baseline, at four, eight and twelve weeks of the treatment, and at the follow-ups at 1-mo, 2-mo and 4-months.;Expected outcome 10: Decreased kinesiophobia, assessed with the Tampa Scale for Kinesiophobia, applied at the baseline, at four, eight and twelve weeks of the treatment, and at the follow-ups at 1-mo, 2-mo and 4-months.;Expected outcome 11: Decreased pain-related catast | — |
Countries
Brazil
Contacts
Public ContactGabriella;Débora Tolentino;Grossi
;
Outcome results
None listed